ライフサイエンスコーパス: mucocutaneous

1 = 71) of the 76 episodes of candidiasis were mucocutaneous.

2 failure syndrome characterized by a triad of mucocutaneous abnormalities and a predisposition to canc

3 failure syndrome characterized by a triad of mucocutaneous abnormalities and an increased predisposit

4 congenita, a rare condition characterized by mucocutaneous abnormalities and bone marrow failure, is

5 telomere attrition in both pedigrees, but no mucocutaneous abnormalities suggestive of DC.

6 characterized by multiple features including mucocutaneous abnormalities, bone marrow failure and an

7 lopecia in addition to the dramatic skin and mucocutaneous acantholysis observed in pemphigus patient

8 tivity, and oral ulcers, and 3 (23%) met the mucocutaneous ACR criteria plus positive antinuclear and

9 uring our study did so mostly by meeting the mucocutaneous ACR criteria, and the majority developed n

10 dermal necrolysis (TEN) are life-threatening mucocutaneous adverse drug reactions characterized by ma

11 and pathologic description of the lichenoid mucocutaneous adverse effects seen in patients receiving

12 mines the clinical spectrum and frequency of mucocutaneous adverse events related to oral sirolimus i

13 Of the 13 patients, 1 (8%) solely met the mucocutaneous American College of Rheumatology (ACR) cri

14 ected population, the reaction timeline, and mucocutaneous and clinical features.

15 13-cRA reports and included mild to moderate mucocutaneous and flu-like symptoms; occasional signific

16 Mucocutaneous and gastrointestinal manifestations were e

17 nary AVM and two brain AVMs, confirming that mucocutaneous and internal organ vascular malformations

18 on Willebrand disease (VWD) with significant mucocutaneous and joint bleeding.

19 ient showed a significant improvement in the mucocutaneous and nail dyspigmentation.

20 le temporal association was observed between mucocutaneous and systemic features, suggesting a new cl

21 s a dimorphic fungus responsible for chronic mucocutaneous and systemic infections.

22 s: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well a

23 yperinflammatory syndrome with dermatologic, mucocutaneous, and gastrointestinal manifestations was a

24 rtality worldwide, manifesting as cutaneous, mucocutaneous, and visceral leishmaniasis.

25 (MIS-C), characterized by gastrointestinal, mucocutaneous, and/or cardiovascular injury occurring we

26 bone marrow failure syndrome associated with mucocutaneous anomalies, pulmonary fibrosis, and cirrhos

27 ders suggest that autoantibodies to specific mucocutaneous antigens are involved.

28 small arteriovenous malformations (AVMs) in mucocutaneous areas (telangiectases) and larger visceral

29 l-mediated, cytotoxic reaction involving the mucocutaneous areas.

30 ly exclusive pathways underlying immunity to mucocutaneous as opposed to invasive fungal infections.

31 molysis bullosa acquisita (EBA) is a chronic mucocutaneous autoimmune skin blistering disease.

32 Using 506 mucocutaneous biopsies collected from patients at three

33 ng phenotype is usually mild and consists of mucocutaneous bleeding at the time when the platelet cou

34 ly tested, however, acute major bleeding and mucocutaneous bleeding during chronic administration wer

35 We investigated the cause of mild mucocutaneous bleeding in a 14-year-old male patient (P1

36 udied a 16-year-old white male with lifelong mucocutaneous bleeding manifestations and abnormal plate

37 The most common adverse event was mucocutaneous bleeding, which was reported in 65% of the

38 is characterized by low platelet counts and mucocutaneous bleeding.

39 ers of platelet function cause petechiae and mucocutaneous bleeding.

40 ofiban for 30 days reported episodes of mild mucocutaneous bleeding.

41 The disorder is characterized by excessive mucocutaneous bleeding.

42 molysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in

43 ne pemphigoid or cicatricial pemphigoid is a mucocutaneous blistering disease characterized by autoan

44 aris (PV) is a potentially lethal autoimmune mucocutaneous blistering disease characterized by bindin

45 phigus vulgaris (PV) is a potentially lethal mucocutaneous blistering disease characterized by cell-c

46 phigus vulgaris (PV) is a potentially lethal mucocutaneous blistering disease characterized by IgG au

47 s vulgaris is a potentially fatal autoimmune mucocutaneous blistering disease.

48 garis (PV) is a potentially fatal autoimmune mucocutaneous blistering disease.

49 nt of CVA6 as the causative agent for severe mucocutaneous blistering reactions mimicking SCAR.

50 s study, we present a patient with extensive mucocutaneous blisters, epidermolytic palmoplantar kerat

51 autoantibodies to type VII collagen causing mucocutaneous blisters.

52 alpha/beta that causes platelet dysfunction, mucocutaneous blood loss and suppression of erythropoies

53 ty to take clopidogrel 75 mg daily without a mucocutaneous, bronchial, or anaphylactic response.

54 cells are also critical in host immunity to mucocutaneous candida infections and Staphylococcus aure

55 tor (AIRE) mutations, manifests with chronic mucocutaneous candidiasis (CMC) and multisystem autoimmu

56 Patients with chronic mucocutaneous candidiasis (CMC) are selectively unable t

57 Chronic mucocutaneous candidiasis (CMC) is characterized by recu

58 in humans have been associated with chronic mucocutaneous candidiasis (CMC), as well as with increas

59 have recently been shown to underlie chronic mucocutaneous candidiasis (CMC), while inborn errors of

60 matophyte infections and suffer with chronic mucocutaneous candidiasis (CMC).

61 such as disseminated candidiasis and chronic mucocutaneous candidiasis (CMC).

62 ukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC).

63 ial disease (hypomorphic alleles) to chronic mucocutaneous candidiasis (CMC; hypermorphic alleles).

64 rge family in which a combination of chronic mucocutaneous candidiasis (fungal infections of the skin

65 Mucocutaneous candidiasis and dermatophyte infections oc

66 Most patients present with severe chronic mucocutaneous candidiasis and organ-specific autoimmunit

67 ator of transcription 1 (STAT1) with chronic mucocutaneous candidiasis and PML was reported previousl

68 ly, it will review key literature on chronic mucocutaneous candidiasis and psoriasis.

69 -17A/F and IL-6 are less common and underlie mucocutaneous candidiasis and staphylococcal diseases, r

70 linkage region on chromosome 2p for chronic mucocutaneous candidiasis and thyroid disease, previousl

71 NCL-EPO-NPs also significantly abrogated mucocutaneous candidiasis by fluconazole-resistant strai

72 cells; meanwhile, some patients with chronic mucocutaneous candidiasis disease might also have viral

73 tor of transcription 1 (STAT1) cause chronic mucocutaneous candidiasis disease.

74 lyendocrine syndrome type-1 (APS-1), chronic mucocutaneous candidiasis has been ascribed to neutraliz

75 Mucocutaneous candidiasis in individuals with IL-17 immu

76 nti-IL-17F, or anti-IL-22 autoantibodies and mucocutaneous candidiasis in the setting of either APECE

77 ing the evolution of isolates from a chronic mucocutaneous candidiasis patient.

78 ciency (AI), hypoparathyroidism, and chronic mucocutaneous candidiasis plus autoantibodies neutralizi

79 ients with unusual susceptibility to chronic mucocutaneous candidiasis resulting from T(H)17 deficien

80 Data on patients affected by chronic mucocutaneous candidiasis underscore the preponderant ro

81 yeast infections and development of chronic mucocutaneous candidiasis were extensively studied.

82 describe 2 patients presenting with chronic mucocutaneous candidiasis who harbor biallelic nonsense

83 d clinical manifestations, including chronic mucocutaneous candidiasis, AI, and asplenia, respectivel

84 matoceles, eczema, staphylococcal abscesses, mucocutaneous candidiasis, and abnormalities of bone and

85 ponses, improved TH17 differentiation, cured mucocutaneous candidiasis, and maintained remission of i

86 rized by multiple endocrine failure, chronic mucocutaneous candidiasis, and various ectodermal defect

87 in IL17F and IL17R in patients with chronic mucocutaneous candidiasis, as well as neutralizing autoa

88 mutations have been associated with chronic mucocutaneous candidiasis, but the role of CARD9 in inte

89 eficiency in mice or humans leads to chronic mucocutaneous candidiasis, but the specific downstream m

90 rent bacterial infections, viral infections, mucocutaneous candidiasis, cutaneous warts, and skin abs

91 In patients with chronic mucocutaneous candidiasis, disease-associated polymorphi

92 In patients with chronic mucocutaneous candidiasis, gain-of-function STAT1 mutati

93 autoimmune disorder characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adren

94 pecies infection, Norwegian scabies, chronic mucocutaneous candidiasis, hypothyroidism, and esophagea

95 About 25% of patients also display mucocutaneous candidiasis, probably owing to impaired in

96 suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal

97 nt, both subjects with mosaicism had chronic mucocutaneous candidiasis, suggesting that candidiasis i

98 17F.S65L) was identified that causes chronic mucocutaneous candidiasis, suggesting the existence of e

99 risingly, it is also associated with chronic mucocutaneous candidiasis, through as yet undetermined m

100 -17A and interleukin-17F (IL-17A/F) underlie mucocutaneous candidiasis, whereas inborn errors of inte

101 utations, including recurrent infections and mucocutaneous candidiasis, which are suggestive of TH17

102 Four patients had recurrent mucocutaneous candidiasis.

103 t linkage assignment of a dominant locus for mucocutaneous candidiasis.

104 hreatening autoimmune cytopenias and chronic mucocutaneous candidiasis.

105 dism, autoimmune adrenocortical failure, and mucocutaneous candidiasis.

106 nic bacterial diseases and interleukin-17A/F mucocutaneous candidiasis.

107 s for immunodeficiency patients with chronic mucocutaneous candidiasis.

108 iseases, including invasive tuberculosis and mucocutaneous candidiasis.

109 entiation (STAT3, STAT1, CARD9) are prone to mucocutaneous candidiasis.

110 owever, they still had infections, including mucocutaneous candidiasis.

111 1 (STAT1) have been associated with chronic mucocutaneous candidiasis.

112 Of the 35 patients, 29 (83%) exhibited mucocutaneous changes, with conjunctival injection (n =

113 entially modulates the host response against mucocutaneous colonizers and potential pathogens, such a

114 ive stomatitis (CUS) is a recently described mucocutaneous condition in which patients experience chr

115 ol for the diagnosis of various inflammatory mucocutaneous conditions for more than 50 years.

116 Mucocutaneous discoloration induced by antiepileptic dru

117 e added to the list of drugs that can induce mucocutaneous discoloration.

118 3DL1(NULL) reduced the risk of having purely mucocutaneous disease (p = 0.0048, OR 0.45, 95% CI 0.25-

119 ratin 14 (K14) promoter, developed GVHD-like mucocutaneous disease and weight loss following transfer

120 Behcet disease can manifest as a purely mucocutaneous disease or can involve other organ systems

121 KS develops as a multifocal mucocutaneous disease with subsequent spread to visceral

122 nts with advanced disease such as widespread mucocutaneous disease, lymphedema, and visceral disease

123 disease, such as in patients with widespread mucocutaneous disease, lymphedema, and visceral disease,

124 g mule deer (Odocoileus hemionus) exhibiting mucocutaneous disease.

125 ug for treatment against CD8 T-cell-mediated mucocutaneous diseases in patients with GVHD.

126 Certain mucocutaneous diseases present with painful, ulcerative,

127 crolysis (TEN) are rare but life-threatening mucocutaneous diseases.

128 significantly less frequent nonopportunistic mucocutaneous disorders and respiratory infections (P<.0

129 Cicatricial pemphigoid is one of a number of mucocutaneous disorders that can present in the oral cav

130 frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and

131 mon human colonizers with a species-specific mucocutaneous distribution.

132 luded generally mild to moderate fatigue and mucocutaneous dryness, moderate to severe neutropenia (3

133 that preferentially infect the cutaneous and mucocutaneous epithelia of vertebrates.

134 HPV infects the squamous or mucocutaneous epithelium; hematogenic spread into other

135 eatment with outcomes of reactive infectious mucocutaneous eruption in hospitalized children and adol

136 We describe the mucocutaneous features and histologic correlation in a p

137 To date, no study has characterized the mucocutaneous features seen in hospitalized children wit

138 te their protean and transient nature, these mucocutaneous features serve as important clues in the r

139 failure disorder characterized by a triad of mucocutaneous features that include abnormal skin pigmen

140 The characterization of mucocutaneous features was verified by 2 board-certified

141 ratosis congenita, typically with associated mucocutaneous features, and others (TERC and TERT) for m

142 one marrow failure syndrome characterized by mucocutaneous features.

143 A detailed awareness of mucocutaneous findings associated with Zika virus infect

144 Recognition of mucocutaneous findings occurred a mean of 2.7 days (rang

145 The duration of mucocutaneous findings varied from hours to days (median

146 ng the COVID-19 pandemic, a wide spectrum of mucocutaneous findings was identified.

147 Neither the presence nor absence of mucocutaneous findings was significantly associated with

148 The most common mucocutaneous findings were generalized sunburn-like ery

149 d clinical characteristics, with emphasis on mucocutaneous findings, of children who met criteria for

150 of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible

151 It is characterized by mild mucocutaneous fragility and blistering and muscle weakne

152 y spectrum encompasses diseases ranging from mucocutaneous fungal infections and psoriasis to combine

153 d with severe disseminated mycobacterial and mucocutaneous fungal infections and was ultimately cured

154 ly from that of Crohn disease (CD); however, mucocutaneous granulomatous lesions have not been consid

155 ted in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis.

156 hrombasthenia is clinically characterized by mucocutaneous hemorrhage with episodes of intracranial a

157 ms involved in host clearance of symptomatic mucocutaneous herpes simplex virus (HSV) infection are u

158 ils and macrophages, respectively, in native mucocutaneous host defenses to S. aureus.

159 famciclovir, and valacyclovir, treatment of mucocutaneous HSV is a practice of everyday medical care

160 through the posthealing phases of recurrent mucocutaneous HSV-2 infection.

161 srupt various cytokine pathways that control mucocutaneous immunity against Candida species, especial

162 indicate that human IL-17RC is essential for mucocutaneous immunity to C. albicans but is otherwise l

163 Mucocutaneous immunity to C. albicans requires T helper

164 tations in either STAT1 or STAT3 that affect mucocutaneous immunity to Candida and Staphylococcus spe

165 In humans, both mucocutaneous immunity to Candida and systemic immunity

166 of IL-17 receptor A (IL-17RA) in preserving mucocutaneous immunity.

167 IL-17F depend on ACT1 to mediate protective mucocutaneous immunity.

168 ular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%)

169 a range of diseases from mild uncomplicated mucocutaneous infection to those that are life threateni

170 from an immunocompromised woman with chronic mucocutaneous infection with ACV-resistant HSV-1.

171 vely, they advance the concept that although mucocutaneous infections are classically caused by immun

172 ons of refractory and/or resistant (R/R) HSV mucocutaneous infections for clinical trial use, the HSV

173 es a wide spectrum of diseases, ranging from mucocutaneous infections like oral thrush to disseminate

174 d fertile and only rarely develop the severe mucocutaneous infections or pulmonary inflammation chara

175 ssing all three selectins (ELP(-/-)) develop mucocutaneous infections that eventually lead to death.

176 amily with 2 siblings who have had recurrent mucocutaneous infections with Candida albicans and Staph

177 ukocyte adhesion deficiency characterized by mucocutaneous infections, plasma cell proliferation, hyp

178 We propose definitions of R/R HSV mucocutaneous infections, which will be subject to re-ev

179 sufficiency, hypoparathyroidism, and chronic mucocutaneous infections.

180 r pharmacological IL-17 deficiencies lead to mucocutaneous infections.

181 hway, conferring susceptibility to recurrent mucocutaneous infections.

182 fense mechanisms for resolution of S. aureus mucocutaneous infections.

183 s infections, EBV+ smooth muscle tumors, and mucocutaneous inflammation, including inflammatory bowel

184 T-cell-mediated oral mucocutaneous inflammatory conditions, including oral li

185 KS causes significant morbidity from mucocutaneous involvement and mortality from complicatio

186 before gentamicin treatment, the patient had mucocutaneous involvement, skeletal and respiratory musc

187 to 20.8%) had pulmonary KS in the absence of mucocutaneous involvement.

188 None had documented mucocutaneous involvement.

189 re was a focus of PCNA-positive cells in the mucocutaneous junction and a few scattered PCNA-positive

190 gland volume and a forward migration of the mucocutaneous junction anterior to the gland orifice; si

191 tival cells remained within 1 to 2 mm of the mucocutaneous junction at all postinjection intervals.

192 at progressively greater distances from the mucocutaneous junction in the animals killed at 1, 3, an

193 Long-term retention of label at the mucocutaneous junction indicates that slow-cycling stem

194 The mucocutaneous junction may provide a therapeutically sig

195 The mucocutaneous junction of the conjunctival epithelium is

196 counted in a series of 0.4-mm zones from the mucocutaneous junction of the eyelid, through the fornix

197 l epithelial stem cells are located near the mucocutaneous junction.

198 es, BrdU-labeled nuclei were retained at the mucocutaneous junction.

199 tibody-mediated blistering disease targeting mucocutaneous keratinocytes (KCs).

200 Patients with mucocutaneous KS and tuberculosis-IRIS experienced great

201 ithout IRIS (+158 vs +53 cells/muL, P = .04, mucocutaneous KS; +261 vs +113, P = .04, tuberculosis).

202 ght a distinct biosignature in patients with mucocutaneous leishmaniasis (MCL) or localized cutaneous

203 localized cutaneous leishmaniasis (LCL) and mucocutaneous leishmaniasis (MCL).

204 nnia) braziliensis is the causative agent of mucocutaneous leishmaniasis (ML) in South America, and M

205 species responsible for the vast majority of mucocutaneous leishmaniasis cases.

206 tive vaccine candidate against VL as well as mucocutaneous leishmaniasis causing parasites.

207 sera from human patients with cutaneous and mucocutaneous leishmaniasis indicated that these individ

208 Appropriate regimens for New World mucocutaneous leishmaniasis need to be established, alth

209 t infection with L. braziliensis that causes mucocutaneous leishmaniasis.

210 virus (VZV) on 695 consecutive cutaneous and mucocutaneous lesion specimens.

211 characterized by the development of multiple mucocutaneous lesions and benign tumors, and enhanced ca

212 ons in the genital tract are responsible for mucocutaneous lesions and transmission and manifest as d

213 Laboratory diagnosis of HSV in cutaneous or mucocutaneous lesions has historically been performed wi

214 Therefore, mucocutaneous lesions in PV patients could be caused by

215 Mucocutaneous lesions of patients with ACV resistance co

216 Mucocutaneous lesions showed necrotizing and proliferati

217 ge of diseases in humans, from uncomplicated mucocutaneous lesions to life-threatening infections.

218 Protection against mucocutaneous lesions was observed, but the dosage was p

219 Twenty-one patients (47%) had more than 50 mucocutaneous lesions, 14 (32%) had lymphedema, and none

220 syphilis is associated with a diffuse rash, mucocutaneous lesions, and lymphadenopathy.

221 All presented with mucocutaneous lesions, most commonly on the genitals (n=

222 s were noted; there was no lower limb edema, mucocutaneous lesions, or palpable lymph node enlargemen

223 ), promotes the rapid regression of advanced mucocutaneous lesions.

224 respiratory symptoms even in the absence of mucocutaneous lesions.

225 D-like disease manifested by weight loss and mucocutaneous lesions.

226 ually associated with a slightly more severe mucocutaneous lipoid proteinosis phenotype, but neurolog

227 Kawasaki disease (KD) or mucocutaneous lymph node syndrome is a vasculitis that m

228 eloped systemic features before the onset of mucocutaneous manifestations and 64 (38.5%) after (n=4 u

229 and marrow transplantation can attenuate the mucocutaneous manifestations of the disease and improve

230 27 (13.7%) presented exclusively with mucocutaneous manifestations without systemic features.

231 cterized by intestinal hamartomatous polyps, mucocutaneous melanin deposition, and increased risk of

232 by gastrointestinal hamartomatous polyps and mucocutaneous melanin pigmentation.

233 he alimentary tract and also is found on the mucocutaneous membranes of the healthy host.

234 the normal flora of the alimentary tract and mucocutaneous membranes, is the leading cause of invasiv

235 tment, remission was induced, notably in the mucocutaneous, musculoskeletal, cardiovascular/respirato

236 ury to multiple organ systems, including the mucocutaneous, musculoskeletal, hematologic, and kidney

237 s did not differ in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs.

238 nosis of ocular and periocular cutaneous and mucocutaneous non-LCH disorders who presented to us over

239 Protocol-defined "minor" bleeding, usually mucocutaneous, occurred in 0% to 32% of patients in the

240 f the patients developed fever, respiratory, mucocutaneous, or central nervous system manifestations.

241 ed by sand fly vectors; it causes cutaneous, mucocutaneous, or visceral disease.

242 cal disease that can present with cutaneous, mucocutaneous, or visceral manifestation and affects mil

243 fragments (scFvs) from a patient with active mucocutaneous pemphigus vulgaris.

244 drome associated with benign tumours, spotty mucocutaneous pigmentation, and endocrine overactivity (

245 hers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 mutations o

246 eutz-Jeghers syndrome (PJS) characterized by mucocutaneous pigmentation, predisposition to benign ham

247 A total of 883 CSF and 452 cutaneous and mucocutaneous prospective, retrospective, and contrived

248 pemphigus vulgaris (PV)-mucosal PV (mPV) and mucocutaneous PV (mcPV).

249 One patient experienced a mucocutaneous reaction described as a Stevens-Johnson sy

250 rt of a disease continuum of vesiculobullous mucocutaneous reactions affecting the skin and mucous me

251 patients who developed widespread blistering mucocutaneous reactions without any suspected drug causa

252 Other features include mucocutaneous scarring and progressive poikiloderma.

253 tency within long-lived neurons and frequent mucocutaneous shedding.

254 HSV was detected in 29% and 4% of mucocutaneous specimens obtained during placebo and vala

255 (HSV-1) and HSV-2 DNA in 1,351 cutaneous and mucocutaneous specimens.

256 Mucocutaneous surfaces rely on IL-17-producing lymphocyt

257 f the epithelial lineage, causing lesions on mucocutaneous surfaces, HSVs also establish latent infec

258 with biallelic RASGRP2 variants had abnormal mucocutaneous, surgical, and dental bleeding from childh

259 ecimens in addition to pharyngeal and rectal mucocutaneous swab specimens.

260 ntiation of HSV-1 and HSV-2 in cutaneous and mucocutaneous swab specimens.

261 significantly less likely to report isolated mucocutaneous symptoms (3% vs. 24%; ratio [95% CI]: 0.1

262 r of vascular malformations characterized by mucocutaneous telangiectases and arteriovenous malformat

263 ity of clinical features, ranging from small mucocutaneous telangiectases to life-threatening viscera

264 ascular disorder characterized by epistaxis, mucocutaneous telangiectases, and arteriovenous malforma

265 ch is characterized by recurrent nosebleeds, mucocutaneous telangiectases, and visceral AVMs and caus

266 in epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and arteriovenous malform

267 s of immune cell positioning in lymphoid and mucocutaneous tissues is the focus of this review.

268 uctures found within the genitalia and other mucocutaneous tissues(1-4).

269 , numerous secondary lesions on the skin and mucocutaneous tissues, severe respiratory disease, death

270 cterial, fungal, and protozoal infections at mucocutaneous tissues.

271 Fungi can cause disease in humans, from mucocutaneous to life-threatening systemic infections.

272 s (PROMs) that evaluate concepts specific to mucocutaneous toxic effects and that allow appropriate i

273 Both regimens were quite toxic, with more mucocutaneous toxicity in the FAP arm and more myelosupp

274 ut an increase in cardiac toxicity, although mucocutaneous toxicity was more common.

275 male, and more likely to have DC-associated mucocutaneous triad features and severe bone marrow fail

276 Dyskeratosis congenita is characterized by a mucocutaneous triad, bone marrow failure (BMF), and pres

277 (n=13) and FS (n=15) patients, and in 79% of mucocutaneous-type PV patients (n=33), but in none of th

278 oma and Epstein-Barr virus positive (EBV(+)) mucocutaneous ulcer are included as new provisional enti

279 hic extranodal LPD were classified as EBV(+) mucocutaneous ulcer.

280 pectively, and 100% for patients with EBV(+) mucocutaneous ulcer.

281 stigated the etiology of autosomal-dominant, mucocutaneous ulceration in a family whose proband was d

282 The treatment of chronic mucocutaneous ulceration is challenging, and only some p

283 pes simplex virus 1 (HSV-1) causes recurrent mucocutaneous ulcers and is the leading cause of infecti

284 g specific types of fungal infections (e.g., mucocutaneous versus systemic).

285 ere localized to healed sites of the vaginal mucocutaneous (VM) tissues.

286 in IL-12Rbeta1 may have candidiasis, usually mucocutaneous, which is frequently recurrent or persiste

287 2.05-3.02] vs respiratory involvement), and mucocutaneous without cardiorespiratory involvement (7.1